Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination

PHASE3CompletedINTERVENTIONAL
Enrollment

472

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 2005

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452)

BIOLOGICAL

HIV-1 Immunogen

Trial Locations (17)

10003

Beth Israel Med. Ctr., ACTU, New York

10016

NY Univ. HIV/AIDS CRS, New York

14642

Univ. of Rochester ACTG CRS, Rochester

19104

Hosp. of the Univ. of Pennsylvania CRS, Philadelphia

21287

Johns Hopkins Adult AIDS CRS, Baltimore

37203

Vanderbilt Therapeutics CRS, Nashville

44106

Case CRS, Cleveland

96816

Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu

275997215

Unc Aids Crs, Chapel Hill

331361013

Univ. of Miami AIDS CRS, Miami

900331079

USC CRS, Los Angeles

941102859

Ucsf Aids Crs, San Francisco

943055107

Stanford CRS, Palo Alto

02114

Massachusetts General Hospital ACTG CRS, Boston

02215

Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston

Brigham and Women's Hosp. ACTG CRS, Boston

Unknown

Bmc Actg Crs, Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00005758 - Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination | Biotech Hunter | Biotech Hunter